Arrowhead Regulatory Filing Sets Up Potential Biotech ETF Shifts

Arrowhead Pharmaceuticals has confirmed plans to move forward with a regulatory filing for plozasiran, a therapeutic candidate designed to address severe hypertriglyceridemia (sHTG). This clinical progression represents a significant step for the company as…